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Background: Extranodal nasal-type NK/T-cell lymphoma is a rare and severe disease. Considering the rarity of this
lymphoma in Europe, we conducted a multicentric retrospective study on nasal-type NK/T cell lymphoma to
determine the optimal induction strategy and identify prognostic factors.
Methods: Thirty-six adult patients with nasal-type NK/T-cell lymphoma were recruited and assessed. In total, 80 %
of patients were classified as having upper aerodigestive tract NK/T-cell lymphoma (UNKTL) and 20 % extra-upper
aerodigestive tract NK/T-cell lymphoma (EUNKTL).
Results: For advanced-stage disease, chemotherapy alone (CT) was the primary treatment (84 % vs. 10 % for
combined CT + radiation therapy (RT), respectively), while for early-stage disease, 50 % of patients received the
combination of CT + RT and 50 % CT alone. Five-year overall survival (OS) and progression-free survival (PFS) rates
were 39 % and 33 %. Complete remission (CR) rates were significantly higher when using CT + RT (90 %) versus CT
alone (33 %) (p< 0.0001). For early-stage disease, CR rates were 37 % for CT alone versus 100 % for CT + RT. Quality
of response was significantly associated with survival, with 5-year OS being 80 % for CR patients versus 0 % for
progressive disease patients (p< 0.01).
Conclusion: Early RT concomitantly or sequentially with CT led to improved patient outcomes, with quality of
initial response being the most important prognosticator for 5-year OS.
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Extranodal nasal-type NK/T-cell lymphoma is a rare and
severe disease, occurring more frequently in Asia and
South America than in Europe and North America [1-4].
This type of disease represents a distinct entity among
T-cell lymphomas according to the World Health
Organization (WHO) classification, [5] being found in
both the nasal cavity and extranasal sites [6-8]. The dis-
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reproduction in any medium, provided the orand necrosis of natural killer (NK) cells or T-cells with
an invariable Epstein-Barr virus (EBV) infection. In pub-
lished studies involving adults with a median age of
50 years, 60-90 % of lymphomas were localized in the
nasal and upper airway regions, with the remaining
found in extranasal sites [2,9,10]. Due to the low inci-
dence of the disease, only a few randomized controlled
trials have been undertaken [11-13]. Previous studies
showed that 5-year overall survival (OS) rates were less
than 40 %, with progression usually occurring within
2 years [2,7,9-15]. However, the early use of sequential
radiotherapy (RT) and chemotherapy (CT) for localized
nasal NK/T-cell [13,16] lymphoma was shown to be a
successful therapy, which cured approximately half of
patients [1,17]. In most patients with advanced diseaseral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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with frequent CT resistance and poor outcome. CHOP-
based therapy [18,19] was often used, but associated
without satisfactory results. However, recent combin-
ation therapies involving L-asparaginase have improved
the outcome in high-risk, refractory, or relapsed patients
[20-22]. The optimal therapy for advanced-stage or
relapsed and refractory disease is yet to be established,
although the results of several recent prospective trials
showed improved results using CT or CT+RT [20,23-
25]. Considering the rarity of this lymphoma in Europe,
we conducted a multicentric retrospective study on
nasal-type NK/T cell lymphoma. To this end, we
reviewed the clinical and biological characteristics as
well as treatments of 36 patients, with outcomes ana-
lyzed according to disease responses in order to deter-




Our study included 36 patients with a median age of
49 years (range: 22 to 80), comprising 24 males and 11
females (ratio: 2.18:1). The majority of patients (75 %)
were younger than 60 years. Among the 36 patients, 29
(80 %) were classified as upper aerodigestive tract NK/T
cell lymphoma (UNKTL) versus 7 (20 %) patients as
extra-upper aerodigestive tract NK/T cell lymphoma
(EUNKTL). In addition, 72 % of UNKTL patients had
local invasiveness greater than T3 with TNM classifica-
tion. According to the Ann Arbor staging system, 10
(28 %) patients were categorized as stage I, six (17 %) as
stage II, and 20 (55 %) as stage IV. All EUNKTL patients
(n = 7) were considered to be stage IV. Furthermore,
75 % of patients had a good performance status (0–1).
The most frequently involved sites were the nose (69 %),
paranasal sinus (58 %), palate-pharyngeal (25 %), and
bones (22 %). Regional lymphadenopathies were involved
in 44 % of cases, bone marrow and central nervous sys-
tem in 22 % and 11 %, respectively. The staging was
based on computer tomography and MRI for most of
the patients. Positron emission tomography/computed
tomography (PET/SCAN) was not used to stage or fol-
low evolution of the disease exept in recent diagnosis of
T/NK lymphoma. The most frequent symptoms at diag-
nosis were obstructive in nature (purulent rhinorrhea,
nasal obstruction, sinusitis, and dysphagia) in addition to
epistaxis and cervical lymphadenopathy. Hematophago-
cytosis was observed in three patients. B symptoms were
present in 39 % of patients. Overall, 14 (39 %) patients
presented lactate dehydrogenase levels above the normal
limit, 18 (50 %) high CRP levels, and 21 (58 %) increased
beta2-microglobulin levels. Lymphopenia was found in
26 (61 %) patients, anemia in 13 (36 %), and low serumalbumin level in 12 (33 %). According to IPI scoring, 23
(64 %) patients were classified as low-risk (0–2) and 13
(36 %) as high-risk. As a bone marrow biopsy was not
performed in one patient, only 35 patients were assessed
using PIT scores, revealing 24 (68 %) patients to be low-
risk versus 11 (32 %) high-risk. According to Korean
Prognostic Index (KPI) scoring, 19 (53 %) patients were
considered low-risk compared to 17 (47 %) high-risk. Pa-
tient characteristics are listed in Table 1.
Treatment modalities
The different first-line CT regimens are presented in
Table 2. CT alone was the primary treatment for
advanced-stage disease (84 % for CT vs. 10 % for CT+
RT), with 82 % of patients receiving anthracycline-based
regimens. For the 35 patients receiving CT, forty differ-
ent protocols were used: anthracycline based regimen,
high dose aracytine plus high dose methotrexate, high
dose methotrexate plus L-asparaginase, cisplatin based
regimen. For early-stage disease, an equal number of
patients received CT+RT or CT alone (50 %-50 %). All
seven patients with EUNKTL were administered CT
alone. For patients with UNKTL, CT alone was given to
17 (61 %) patients compared to 10 (36 %) receiving the
combination of CT+RT. Patients were treated with a
median of 2 CT lines (range: 1 to 4). One patient was
lost of view after 6 cycles of chemotherapy without
evaluation of the disease response.
Radiation therapy and modalities
Ten patients received CT+RT. The RT was given with a
median dose of 40 gray (40 to 46). Only one patient
received RT alone (30 gray) plus corticosteroids because
of advaned age and comorbidities.
Response to treatment
At the end of treatment, complete remission (CR) was
observed in 48 % of patients, while the remaining 52 %
experienced partial response or progressive disease. For
the entire cohort, CR rates were 33 % for CT alone com-
pared with 90 % for RT+CT.. In the CT group, there
was no significant difference (p= 0.77) in CR rates
according to the type of regimen: 52 % of patients
achieved CR with an anthracycline-based regimen, 66 %
with the combination of methotrexate and L-
asparaginase, and 34 % with cisplatin-based regimens
For UNKTL patients, CR rates were only 50 % for CT
alone versus 90 % for RT+CT.. However, UNKTL
patients with CT+RT have more favorable prognostic
parameters than CT alone patients: 20 % stage IV versus
61 %, 10 % of elevated LDH versus 44 %; but the same
percentage of local invasiveness and regional lymph-
adenopathy involved (70 % vs 67 % and 40 % vs 44 %,
Table 1 Clinical characteristics of the 36 patients
diagnosed with NK/T cell lymphoma 'nasal type'
Number of patients 36
Median age (years ; range) 49 (22–80)
Age > 60 years, n (%) 9 (25)
Gender (male – female) 24 – 11
WHO performance status, n (%)
0- 1 27 (75)
2 6 (17)
3–4 3 (8)
Local invasiveness in Upper
NK / T lymphoma: T3 and T4, n (%)
21 (72)
Signs and symptoms, n (%)
Purulent rhinorrhea 20 (55)




Orbital edema or uveitis 5 (14)
Dysphagia 2 (5)
Nerve VII, palsy 2 (5)
B symptoms, n (%) 14 (39)
Anatomic category, n (%)
Upper NK/T lymphoma 29 (80)
Extra upper NK/T lymphoma 7 (20)
Sites of localization, n (%)
Nose 25 (69)
Paranasal sinus 21 (58)
Nodes 16 (44)
Palate – pharyngeal 9 (25)




Central nervous involvement 4 (11)
Liver 4 (11)




Regional lymphadenopathy, n (%) 16 (44)
Biology, n (%)
LDH > Upper limit of normal 14 (39)
Lymphopenia 22 (61)
B2 microglobuline > upper limit of normal 21 (58)
CRP > upper limit of normal 18 (50)
Table 1 Clinical characteristics of the 36 patients
diagnosed with NK/T cell lymphoma 'nasal type'
(Continued)
Anemia 13 (36)
Serum albumin <30 mg/L 12 (33)
Hemophagocytic syndrome, n (%) 3 (8)




IPI score, n (%)
0 – 1 (low risk) 16 (44)
2 (low intermediate risk) 7 (20)
3 (high intermediate risk) 7 (20)
4 -5 (high risk) 6 (16)
Korean NK/T cell prognostic index, n (%)
0 (low risk) 5 (14)
1 (low intermediate risk) 14 (39)
2 (high intermediate risk) 8 (22)
3 – 4 (high risk) 9 (25)
PIT score, n (%)
0 (low risk) 13 (37)
1 (low intermediate) 11 (31)
2 (high intermediate risk) 8 (22)
3 – 4 (high risk) 3 (8)
IPI : International Prognostic Index, PIT : Prognostic Index for PTCL/NOS, LDH :
Lactate dehydrogenase.
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enced disease progression on this regimen.
Among the low stage group (stage I-II), the distribu-
tion between the two treatment modalities is balanced
confirming the better outcome with the combination
CT+RT. However in the stage IV patients, the differ-
ence in the distribution between CT and CT+RT could
create a significant bias in favor of the CT+RT group.
For EUNKTL patients, all were treated with
anthracycline-based regimens, resulting in a CR rate of
43 %. Responses to the different modalities are provided
in Table 3.
Overall survival and progression-free survival
The 5-year OS and PFS rates were 39 % and 33 %, re-
spectively (Figure 1A and Figure 1B). Eighty-two percent
of patients died from disease progression, one from ab-
dominal infection, and one from secondary acute
leukemia 6 years after autologous transplantation. In
univariate analysis, male sex, B symptoms, disease stage,
lactate dehydrogenase level, prognostic indexes (IPI, PIT,
and KPI), and quality of response (CR versus no re-
sponse (or PD)) were found to be significantly associated
Table 2 First line treatment of the patients with T/NK cell lymphoma
Number of patients n (%) Stage I -II n (%) Stage IV n(%) UNKTL n (%) EUNKTL n (%)
First line therapy 36 (100) 16 (45) 20 (55) 29 (80) 7 (20)
Chemotherapy alone 25 (69) 8 (50) 17 (85) 18 (62) 7 (100)
Chemotherapy + radiotherapy 10 (28) 8 (50) 2 (10) 10 (35) 0
Radiotherapy alone 1 (3) 0 1 (5) 1 (3) 0
Anthracycline-based regimen 26 (74) 11 (69) 15 (79) 20 (71) 6 (86)
High-dose methotrexate + high-dose
aracytine regimen
4 (11) 2 (12) 2 (11) 3 (11) 1 (14)
High-dose methotrexate + L-asparaginase 2 (6) 1 (7) 1 (5) 2 (7) 0
Cisplatin-based regimen 3 (9) 2 (12) 1 (5) 3 (11) 0
UNKTL: upper aerodigestive NK/T cell lymphoma, EUNKTL : extra-upper aerodigestive NK/T cell lymphoma.
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ness, high lactate dehydrogenase levels, and high-risk
scores according to the IPI, PIT, and KPI classifications
were related to poor survival. Quality of response was
significantly associated with survival, with 5-year OS
rates being 80 % for patients in CR versus 0 % for those
with progressive disease (p< 0.01). When we focused on
the UNKTL population, the best results were obtained
when treatment consisted of CT+RT, with a statistically
significant difference in terms of 5-year OS and PFS.
The 5-year OS rate was 75 % for patients receiving CT+Table 3 Response rate after first line therapy in patient
with NK/T lymphoma
Response
CR (%) PD (%)
All patients
First line therapy 48 52
Chemotherapy alone 33 67
Chemotherapy + radiotherapy 90 10
Radiotherapy alone 0 100
Stage I and II 69 31
Chemotherapy alone 37 63
Chemotherapy + radiotherapy 100 0
Stage IV 31 69
Chemotherapy alone 31 69
Chemotherapy + radiotherapy 50 50
Radiotherapy alone 0 100
UNKTL 50 50
Chemotherapy alone 29 71
Chemotherapy + radiotherapy 90 10
Radiotherapy alone 0 100
EUNKTL
Chemotherapy alone 43 57
OR: overall response, PD: progressive disease, UNKTL: Upper NK/T Lymphoma,
EUNKTL: Extra Upper NK/T Lymphoma 35 patients analyzed because 1 patient
lost of view for response.RT compared with 35 % for those receiving CT alone
(p = 0.041) (Figure 2A). Accordingly, PFS was signifi-
cantly higher in patients treated with RT+CT versus CT
alone (p=0.0063) (Figure 2B). Lymphopenia, low serum al-
bumin level, high CRP level, and the classification into
UNKTL or EUNKTL were statistically linked to OS or PFS.
Discussion
Extranodal nasal-type NK/T-cell lymphoma is consid-
ered a distinct clinicopathological entity according to the
WHO classification of lymphoid tumors, being more fre-
quent in Asia and Central and South America than in
Western countries [2,3,5,9,17,26]. In a recent inter-
national multicenter study reported by the International
Peripheral T-cell Lymphoma Project, median survival
time for patients with NK/T-cell lymphoma was
8 months, being the worst among all peripheral T-cell
lymphomas included in the study [17]. To date, only a
few studies have compared the clinical and pathologic
features of patients with nasal or extranasal disease
[7,10,17].
In our study, 36 French patients, all of European des-
cent, observed over a 22-year period were diagnosed
with nasal-type NK/T cell lymphoma..Main patient char-
acteristics, such as age, sex ratio, B symptoms, and clin-
ical aspects of the disease, were comparable to those
previously reported [17,27,28]. At diagnosis, 80 % of
tumors involved the upper aerodigestive tract, including
the nasal and oral cavity, as well as the naso-, oro- and
hypopharynx, while 20 % were extranasal. Disease pres-
entation in our population was aggressive, with 65 % of
UNKTL patients presenting stage IV at diagnosis. Al-
though extranasal cases presented more adverse clinical
features, no statistical differences were found in terms of
OS or PFS between UNKTL and EUNKTL patients. This
absence in OS difference may be accounted for by the
more advanced disease stage of the UNKTL population.
Previous studies reported bone marrow and central ner-
vous system involvement at presentation to be rare,
affecting 3 % and 7 % of cases, respectively [8,29-31]. In
A. Overall survival   
B. Progression Free Survival 
Figure 1 (A) Overall survival (OS) for the entire cohort. (B) Progression-free survival (PFS) for the entire cohort.
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A. Overall survival according to type of treatment  
B. Progression free survival according to type of treatment 
Figure 2 (A) Overall survival according to type of treatment. CT: chemotherapy; RT: radiotherapy; CT + RT: chemotherapy plus radiotherapy.
(B) Progression-free survival according to type of treatment.
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system involvement was observed in 22 % and 11 % of
patients, respectively. However, regional node involve-
ment was found to be more frequent, affecting 44 % of
patients [32,33]. In line with previous studies, we identi-
fied several variables associated with poor survival, not-
ably regional lymph node involvement [34], local
invasiveness [34-37], elevated lactate deshydrogenase
[1,34], poor performance status [1], and B symptoms
[1,37,38].
Several staging systems have been proposed in respect
to nasal NK/T-cell lymphoma in order to predict prog-
nosis. The Ann-Arbor staging system, while designed
mainly for Hodgkin lymphoma, is not always accurate in
the case of NK-cell lymphomas. In a number of studies
on nasal NK-cell lymphoma, the involvement of areas
outside the nasal cavity, including the paranasal sinuses,
nasopharynx, and orbits, was defined as stage IE disease.
In this case, the Ann-Arbor staging system cannot be
used to determine the extent of the disease. Thus, for
our patients, we scored local invasiveness greater than
or equal to T3 according to the TNM classification.
Overall, 72 % of UNKTL patients had a local invasive-
ness>T3, which was associated with worse survival.
Several studies investigated the impact of IPI in
patients with nasal NK/T-cell lymphoma [7,9,13]. How-
ever, the use of this index has been controversial
[13,34,39,40], as in a number of studies, only a small
proportion of NK/T-cell lymphoma patients (up to 7 %)
were categorized as high-risk [1,13,34,41,42]. Assigning a
conventional IPI score appears to be of limited value,
since most cases of NK/T-cell lymphomas are localized
and result in a low score, despite survival being poor.
Lee et al. [9] developed the KPI, a prognostic model
based on four risk factors: B symptoms, advanced stage,
elevated lactate dehydrogenase levels, and involvement
of regional lymph nodes. When analyzed according to
the number of risk factors, the 5-year OS rate was 81 %
for patients with no risk factors (score 0) and 7-15 % for
those with three to four (scores 3–4). Our data validated
the prognostic impact of the KPI, with 5-year OS rates
being 60 % for patients with score 0 versus 17 % for
those with score 4. This index appears more accurate than
the IPI score in distinguishing high-risk groups, potentially
being the most appropriate prognostic scoring system for
patients with nasal-type NK/T lymphoma [43].
There are currently a few randomized trials evaluat-
ing the different therapeutic options for nasal-type
NK/T-cell lymphomas. The majority of studies are retro-
spective in nature and almost all are conducted in the
geographical areas where the tumor is prevalent. Most
authors reported on the use of RT alone or combined
with CT, with RT being associated with high remission
rates and prolonged survival, mainly in the case oflocalized disease [34,40,44,45]. In a study of 82 patients
with localized disease, early RT was shown to be the
only independent prognostic factor, with 5-year OS
being significantly better in patients receiving >54 Gy
[46]. There appears to be a consensus that the optimal
dose is 50 Gy, to be delivered to both the nasal cavity
and sinuses. Nevertheless, concurrent CT may improve
both local and systemic disease control. When compar-
ing CT alone to RT alone or CT+RT, CR rates were sig-
nificantly higher in patients treated with CT+RT
[13,28,34,44,47]. In addition, two recent reports on CT+
RT for localized disease (stage IE to IIE) showed
improved results compared to the historical controls
using RT alone [24,48].
In our study, the overall response rate was 48 %, with
progressive disease observed in 52 % of patients and no
partial response. Combined therapy comprising RT and
anthracycline-based CT regimens was associated with
higher CR rates and longer OS compared to CT or RT
alone, even in advanced-stage disease (CR rate of 31 %
vs 50 % for CT and CT+RT, respectively). However,
the CT+RT cohort has a better prognostic profile than
the CT population and this difference will create a sig-
nificant bias in favor of CT+RT group, especially for
this high stage group. No CR was recorded for RT
alone, although this treatment was only administered to
one elderly patient with a non optimal dose of 40 Gy.
In the two published metaanalyses, first-line CT regi-
mens involved CHOP, CHOP-like schedules, etoposide,
ifosfamide, or cisplatin. In our study, however, the dis-
ease did not respond well to these combinations. The
introduction of L-asparaginase-containing regimens led
to further improvements, as most studies using
asparaginase-based regimens in a relapsed or refractory
setting reported response rates of around 50 %, with
5-year OS being 65 % (86 % for localized disease and
38 % for advanced stage) [20,22,25,48-50]. In our study,
the different CT regimens were compared, with no stat-
istical difference (but low numbers of patients in each
type) found in CR rates according to the type of regi-
men. The use of L-asparaginase-based regimens in in-
duction therapy did not improve CR rates, although only
four patients were administered this regimen. Data
regarding the use of L-asparaginase as first-line therapy
is therefore still needed.
For all patients, 5-year OS and PFS rates were 39 %
and 33 %, respectively. In addition, the quality of re-
sponse after first-line treatment was found to be crucial
for survival, with 5-year OS being 80 % in CR patients
compared to 0 % in progressive disease patients.
Conclusions
In our study, the early use of RT concomitantly or se-
quentially with CT was shown to improve patient
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even in patients presenting aggressive forms. Based on
these positive results, patients with localized disease
should be administered RT+CT. The use of L-
asparaginase-based regimens as first-line therapy should
be considered for patients with disseminated disease, al-
though prospective trials are still needed to confirm
improved survival rates associated with this therapeutic
approach.
Patients and Methods
Patients and staging evaluation
Between January 1989 and September 2010, 36 patients
were recruited in seven hematological centers in France.
All the patients in this series been entirely of European
descent (no patients were of Asia or south America des-
cent). Patients were required to fulfill the WHO criteria
for clinicopathologic diagnosis and classification of NK/
T-cell lymphoma [5]. All biopsied tissues were critically
reviewed. The following data was collected: gender, age,
clinical characteristics (performance status and symp-
toms), biological parameters (lactate dehydrogenase, C-
reactive protein [CRP], and serum albumin), radiological
presentation, and histopathological reports describing
angiocentricity, angioinvasion, necrosis zones, and poly-
morphism of individual cells. Immunohistochemical
studies had to be positive for NK/T-cell markers, includ-
ing CD2, CD3, or CD56 cytotoxic molecule (TIA-1 or
granzyme B), and for EBV-encoded small RNA, and
negative for B-cell markers, such as CD20 or CD79.
Patients with blastic NK-cell lymphoma/leukemia, ag-
gressive NK-cell lymphoma/leukemia, and unspecified
peripheral T-cell lymphoma were excluded from the
analysis. Scores for the International Prognostic Index
[51] (IPI), Korean Prognostic Index (KPI) [9], and Prog-
nostic Index for PTCL/NOS [52] (PIT) were calculated
for all patients. We separately analyzed the survival of
patients with upper aerodigestive tract NK/T-cell lymph-
oma (UNKTL) and extra-upper aerodigestive tract NK/
T-cell lymphoma (EUNKTL) [1,27]. UNKTL included all
lymphomas confined to the nasal cavity, nasopharynx,
and upper aerodigestive tract, whereas lymphomas at all
other sites were considered to be EUNKTL. Patients
with primary lesions within the nasal cavity and second-
ary lesions in other organs were classified as UNKTL.
Local invasiveness was defined in accordance with the
2002 TNM classification of the American Joint Commit-
tee on Cancer [9].
Outcomes and treatment strategies
CT schedules, RT dosages, and chronological sequence
of treatments were analyzed for each patient. In terms of
CT, treatments were based on anthracycline, aracytine
or cisplatin regimens (doxorubicin, cyclophosphamide,vindesine, bleomycin, and prednisone [ACVBP]) for 17
(49 %) patients; cyclophosphamide, doxorubicin, vincris-
tine, and prednisone (CHOP) for 9 (25 %) patients;
cyclophosphamide, vincristine, prednisone, doxorubicin,
and methotrexate (COPADM) followed by cyclophos-
phamide, cytosine arabinoside, and etoposide (CYVE)
for four (11 %) patients; etoposide, methylprednisolone,
cytosine arabinoside, and cisplatin (ESHAP) and dexa-
methasone (DHAP) for 3 (8.3 %) patients; high-dose
methotrexate plus L-asparaginase for 2 (6 %) patients.
Autologous bone marrow transplantation was performed
as first-line consolidation on one patient. The different
treatment schedules are listed in Table 2. Studied out-
comes were treatment response, progression-free sur-
vival (PFS), and OS, with treatment response being
evaluated at the end of treatment according to the stan-
dardized response criteria of Cheson et al. [53].
Regarding RT treatment, the median dose was 40
grays (Gy). All patients received RT from a linear accel-
erator with 4 megavolt (MV), 6 MV or 10 MV photons
to achieve dose homogeneity. Generally, the planning
target volume included all macroscopic lesions, the para-
nasalsinuses, the nasopharynx, the upper gum, and the
palate with adequate margins. Regardless of primary
tumor localization, elective cervical lymph node irradi-
ation was not delivered unless the neck was involved
clinically. The most common field arrangement was two
lateral opposing photons fields with supplementation be-
tween the medial canthus by appropriate energy of
electron.
Statistical analysis
OS and PFS were estimated using the Kaplan-Meier
product-limit method. OS was measured from the date
of diagnosis to death or last follow-up visit. Unadjusted
Cox proportional hazards models were employed to
make group comparisons for baseline and treatment
characteristics and Kaplan –Meier curves were used to
quantify the percentage of patients who were free of re-
currence or those who stay alive over time. A p-value
<0.05 was considered statistically significant, with two-
sided significance tests used for all p-values.
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